Motexafin gadolinium
From Wikipedia, the free encyclopedia
Motexafin gadolinium
|
|
Systematic (IUPAC) name | |
? | |
Identifiers | |
CAS number | |
ATC code | ? |
PubChem | |
Chemical data | |
Formula | C52H72GdN5O14 |
Mol. mass | 1148.403 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Motexafin gadolinium (proposed tradename Xcytrin) is an inhibitor of thioredoxin reductase and ribonucleotide reductase. It has been proposed as a possible chemotherapeutic agent in the treatment of brain cancer.[1]
[edit] History
On May 9, 2006, a New Drug Application was submitted to the United States Food and Drug Administration (FDA) by Pharmacyclics, Inc.[2]
On December 2007, the FDA issued a not approvable letter for motexafin gadolinium.[3]
[edit] References
- ^ Richards G, Mehta M (2007). "Motexafin gadolinium in the treatment of brain metastases". Expert opinion on pharmacotherapy 8 (3): 351–9. doi: . PMID 17266469.
- ^ Pharmacyclics, Inc. press release - Pharmacyclics to Submit New Drug Application for Xcytrin for Treatment of Lung Cancer Patients With Brain Metastases
- ^ Pharmacyclics, Inc. press release - Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases